iCAD (ICAD) Upgraded at ValuEngine
iCAD (NASDAQ:ICAD) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Thursday.
iCAD (NASDAQ ICAD) traded up $0.44 during mid-day trading on Thursday, reaching $4.00. 78,021 shares of the company traded hands, compared to its average volume of 61,067. iCAD has a fifty-two week low of $3.13 and a fifty-two week high of $6.07. The firm has a market capitalization of $57.29, a price-to-earnings ratio of -4.94 and a beta of 1.54. The company has a current ratio of 1.95, a quick ratio of 1.67 and a debt-to-equity ratio of 0.31.
iCAD (NASDAQ:ICAD) last released its earnings results on Wednesday, November 8th. The technology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. iCAD had a negative net margin of 49.16% and a negative return on equity of 47.31%. The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.43 million. equities analysts forecast that iCAD will post -0.62 earnings per share for the current year.
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.